Comparison of In-vitro Penetration of Transdermal Patch Containing Pure Diclofenac Sodium and Nanoparticles as Analgesic and Anti-Inflammatory
Objective: Diclofenac sodium is a Non Steroid Anti Inflammatory class of drug which has a weakness in oral use in the form of irritation of the digestive tract. This study aims to make transdermal patches containing pure sodium diclofenac and nanoparticles with ethyl cellulose (EC) and polyvinyl pyrrolidone (PVP) polymers and compare in-vitro penetration using franz diffusion cells.
Design: This research is an experimental research which will be calculated quantitatively percent cumulative penetration of pure diclofenac sodium and nanoparticles from the transdermal patch for 8 hours.
Intervention: The variables that play a role in this research are pure diclofenac sodium and nanoparticles, both using and without enhancers
Main outcome measures: In this study, the main measurement is the absorbance value of diclofenac sodium using a spectrophotometer, which penetrates the skin on franz diffusion cells and is converted to percent cumulative penetration.
Result: Transdermal patches containing diclofenac sodium nanoparticles have a higher cumulative percent penetration (58.87 ± 0.7458%) than transdermal patches containing pure sodium diclofenac (46.6 ± 1.9438%), but not higher than transdermal patches containing pure sodium diclofenac with the addition of propylene glycol enhancers (67.59 ± 1.4675%). The three transdermal patch formulas did not differ significantly to the percent cumulative drug penetration (p> 0.05).Transdermal patches containing diclofenac sodium nanoparticles have a higher analgesic and anti-inflammatory effect than transdermal patches containing pure sodium diclofenac up to 480 minutes.
Conclusion: Transdermal patches containing sodium diclofenac nanoparticles have been shown to be able to increase drug penetration through the rabbit's stomach skin membrane in-vitro using Franz diffusion cells. Transdermal patches of pure diclofenac sodium and nanoparticles provided analgesic and anti-inflammatory effects that were significantly different from negative control.
2. Rajabalaya, R., Khanam, J. & Nanda, A. Design of a matrix patch formulation for long-acting permeation of diclofenac potassium. Asian J. Pharm. Sci.2008; 3:30–39.
3. WHO. Chronic rheumatic conditions. World Health Organization (WHO) https://www.who.int/chp/topics/rheumatic/en/ (2019).
4. Sachan, R. & Bajpai, M. Transdermal Drug Delivery System : A Review.2013; 3:748–765.
5. Sheth, N. S. & Mistry, R. B. Formulation and evaluation of transdermal patches and to study permeation enhancement effect of eugenol. J. Appl. Pharm. Sci.2011; 01:96–101.
6. Bhowmik, D., Pusupoleti, K. R., Duraivel, S. & Kumar, K. P. S. Recent Approaches in Transdermal Drug Delivery System.2013; 2:99–108.
7. Rastogi, V., Pragya & Upadhyay, P. A Brief View On Antihypertensive Drugs Delivery Through Transdermal Patches. Int. J. Pharm. Sci. Res.2012; 3:1955–1970.
8. Taghizadeh, S. M. & Bajgholi, S. A New Liposomal-Drug-in-Adhesive Patch for Transdermal Delivery of Sodium Diclofenac. 2011; 576–581.
9. Singh, A. K., Yadav, T. P., Pandey, B., Gupta, V. & Singh, S. P. Chapter 15 - Engineering Nanomaterials for Smart Drug Release: Recent Advances and Challenges. Applications of Targeted Nano Drugs and Delivery Systems (Elsevier Inc., 2019). doi:10.1016/B978-0-12-814029-1.00015-6.
10. Sharma, M. Chapter 18 - Transdermal and Intravenous Nano Drug Delivery Systems: Present and Future. Applications of Targeted Nano Drugs and Delivery Systems (Elsevier Inc., 2019). doi:10.1016/B978-0-12-814029-1.00018-1.
11. Bibi, N., Ahmed, N. & Khan, G. M. Chapter 21 - Nanostructures in transdermal drug delivery systems. Nanostructures for Drug Delivery (Elsevier Inc., 2017). doi:10.1016/B978-0-323-46143-6/00021-X.
12. Ashok, S., Sebuah, J., Satyappa, S., Sebuah, J. & Ashok, A. Journal of Pengiriman Obat Sains dan Teknologi fabrikasi dan in-vivo evaluasi nanocarriers lipid berdasarkan transdermal patch colchicine. 2017; 41:444–453.
13. Yadav, V. Transdermal Drug Delivery System: Review. Int. J. Pharm. Sci. Res.2012; 3:376–382.
14. Muñoz, M. D., Castán, H., Ruiz, M. A. & Morales, M. E. Design, development and characterization of transdermal patch of methadone. J. Drug Deliv. Sci. Technol. (2017) doi:10.1016/j.jddst.2017.04.011.
15. Swain, R. P., Nagamani, R. & Panda, S. Formulation , in vitro Characterization and Stability Studies of Fast Dispersing Formulation , in vitro Characterization and Stability Studies of Fast Dispersing Tablets of Diclofenac Sodium. J. Appl. Pharm. Sci.2015; 5:094–102.
16. Lakhani, P., Bahl, R. & Bafna, P. Transdermal Patches: Physiochemical And In-Vitro Evaluation Methods. Int. J. Pharm. Sci. Res.2015; 6.
17. Mahajan, N. M. et al. Formulation development and evaluation of transdermal patch of piroxicam for treating dysmenorrhoea. J. Appl. Pharm. Sci.2018; 8:35–41.
18. Lintang, K., Panal, S. & Aminah, D. Asian Journal of Pharmaceutical Research and Development. Asian J. Pharm. Res. Dev.2019;7:1–5.
19. Alkilani, A. Z., Mccrudden, M. T. C. & Donnelly, R. F. Transdermal Drug Delivery: Innovative Pharmaceutical Developments Based on Disruption of the Barrier Properties of the stratum corneum. Pharmaceutics.2015;7:438–470 (2015).
20. Parthasarathy, G., Reddy, K. B. & Prasanth, V. V. Formulation And Characterization Of Transdermal Patches of Naproxen With Various Polymers. Pharm. Glob. Int. J. Compr. Pharm.2011; 2:1–3.
21. Walker, B. & Smith, E. W. The role of percutaneous. Adv. Drug Deliv. Rev. 1996; 295–301.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).